News

Public · Published

Oppenheimer maintains BioMarin Pharmaceutical at Outperform, lowers price target to $94 from $97

Oppenheimer kept its Outperform rating on BioMarin Pharmaceutical but lowered its price target to $94 from $97, a 3.1% decrease. The new target implies 63.6% upside from the November 2 close of $57.44.

Published:

Updated:

What happened

Oppenheimer kept its Outperform rating on BioMarin Pharmaceutical but lowered its price target to $94 from $97, a 3.1% decrease. The new target implies 63.6% upside from the November 2 close of $57.44.

Confirmed

Global impact / market context

A lower target still sits far above the current share price, so Oppenheimer sees large potential gains while trimming its optimism slightly. Because other recent targets range from $60 to $122, investors face widely split views on BioMarin's value.

Analyst inference

The five most recent analyst notes show targets from $60 to $122, with several firms neutral or holding. That spread means opinion on BioMarin is divided, and Oppenheimer's small cut keeps it among the more bullish views rather than signaling a broad downgrade.

Analyst inference

What to watch

  1. Watch whether other firms change their BioMarin ratings or price targets after Oppenheimer's cut, since the five latest notes range from $60 to $122. Confirmed
  2. Track BioMarin's next company updates on revenue, costs, and product progress, because analysts may adjust targets if results differ from what they expect. Proposed
  3. Watch the gap between the $57.44 close and higher targets; if the share price moves toward $94, it would suggest investors are pricing in more of Oppenheimer's upside view. Analyst inference

Evidence

  • Original source link unavailable